

# Daniel Barrowdale

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7976309/daniel-barrowdale-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

4,465  
citations

26  
h-index

57  
g-index

57  
ext. papers

5,890  
ext. citations

12.2  
avg, IF

3.26  
L-index

#	Paper	IF	Citations
52	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 2402-2416	27.4	1140
51	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 371-84, 384e1-2	36.3	422
50	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , <b>2010</b> , 42, 885-92	36.3	276
49	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	239
48	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003212	6	209
47	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 680-691	36.3	190
46	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 1767-1778	36.3	186
45	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 164-71	36.3	177
44	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	153
43	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , <b>2018</b> , 39, 593-620	4.7	138
42	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2240-2250	2.2	101
41	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , <b>2016</b> , 48, 374-86	36.3	93
40	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003173	6	90
39	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 3419	8.3	82
38	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , <b>2020</b> , 52, 572-581	36.3	76
37	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R33	8.3	70
36	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 11375	17.4	64

35	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 15	8.3	58
34	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , <b>2020</b> , 52, 56-73	36.3	56
33	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , <b>2016</b> , 7, 12675	17.4	53
32	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. <i>European Urology</i> , <b>2020</b> , 77, 24-35	10.2	53
31	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 1741	17.4	47
30	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 3416	8.3	46
29	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 1653-1666	8.1	34
28	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004256	6	33
27	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. <i>Genetics in Medicine</i> , <b>2017</b> , 19, 30-35	8.1	31
26	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120020	3.7	26
25	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>JAMA Oncology</i> , <b>2020</b> , 6, 1218-1230	13.4	25
24	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 64	8.3	25
23	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 8	8.3	22
22	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , <b>2020</b> , 80, 624-638	10.1	22
21	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 350-364	9.7	22
20	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 308-16	4	20
19	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 61	8.3	16
18	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 386-401	4.9	15

17	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. <i>European Journal of Human Genetics</i> , <b>2017</b> , 25, 432-438	5.3	15
16	Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 1330-3	5.3	15
15	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 161, 117-134	4.4	15
14	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 180-192	8.7	13
13	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky023	4.6	13
12	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. <i>Genetics in Medicine</i> , <b>2018</b> , 20, 1575-1582	8.1	12
11	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 38	7.8	12
10	Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 1018-24	4	12
9	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , <b>2020</b> , 44, 442-468	2.6	9
8	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 368-378	4	9
7	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 225, 51.e1-51.e17	6.4	9
6	The European Genome-phenome Archive in 2021. <i>Nucleic Acids Research</i> , <b>2021</b> ,	20.1	5
5	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , <b>2021</b> , 12, 1078	17.4	4
4	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
3	Prostate Cancer Risk by BRCA2 Genomic Regions. <i>European Urology</i> , <b>2020</b> , 78, 494-497	10.2	2
2	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , <b>2021</b> , 23, 1726-1737	8.1	2
1	Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1558-1558	2.2	